ASCO GU 2022

ASCO GU 2022
February 17-19, 2022
Virtual & San Francisco, CA

American Society of Clinical Oncology Genitourinary Cancers Symposium.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (4)

    TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.

    • Author(s): Grivas, P
    • trodelvy
    • Oncology

    TROPHY-U-01 Cohort 4

    • Author(s): Tagawa, S
    • trodelvy
    • Oncology

    TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy.

    • Author(s): Vulsteke, C
    • trodelvy
    • Oncology

    A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors

    • Author(s): Subbiah, V
    • magrolimab
    • Oncology